Author Correction: The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology

Affiliations

• ¹ Department of Oncology and Pathology, Karolinska Institutet, Science for Life Laboratory, Stockholm, Sweden. david.tamborero@ki.se.
• ² Medical Oncology, Oncology Data Science, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
• ³ Department of Oncology and Pathology, Karolinska Institutet, Science for Life Laboratory, Stockholm, Sweden.
• ⁴ Hereditary Cancer Genetics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
• ⁵ Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
• ⁶ Department of Oncology and Pathology, Karolinska Institutet, Theme Cancer, Karolinska Comprehensive Cancer Center, Karolinska University Hospital, Stockholm, Sweden.
• ⁷ Cancer Research UK Cambridge Centre, Cambridge, UK.
• ⁸ Département d'Innovation Thérapeutique et d'Essais Précoces, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
• ⁹ The Netherlands Cancer Institute, Amsterdam, the Netherlands.
• ¹⁰ NCT Trial Center, German Cancer Research Center, Heidelberg University Hospital, Heidelberg, Germany.
• ¹¹ Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
• ¹² IFOM, FIRC Institute of Molecular Oncology, Milan, Italy.
• ¹³ Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
• ¹⁴ Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
• ¹⁵ Scientific Directorate, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
• ¹⁶ National Center for Tumor Diseases Heidelberg, German Cancer Research Center, Heidelberg, Germany.
• ¹⁷ Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.
• ¹⁸ Department of Hematology, Karolinska University Hospital, Stockholm, Sweden.
• ¹⁹ Oncode Institute, Utrecht, the Netherlands.
• ²⁰ Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ²¹ Clinical Proteomics Unit, Department of Oncology and Pathology, Karolinska Institutet, Science for Life Laboratory, Karolinska University Hospital, Stockholm, Sweden. janne.lehtio@ki.se.